Update: New uses for lithium and anticonvulsants

CNS Spectrums

Volumn 12, Issue 11, 2007, Pages 831-841

  Rosenberg, Jennifer M ^a,b,d   Salzman, Carl ^c  

^a Front Range Clinical Research   (United States)

^b Jefferson Center for Mental Health   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BARBITAL; BENZODIAZEPINE; CARBAMAZEPINE; CLOMETHIAZOLE; CLOMIPRAMINE; FLUVOXAMINE; GABAPENTIN; LITHIUM; LORAZEPAM; OXAZEPAM; PLACEBO; TIAGABINE; TOPIRAMATE; VALPROATE SEMISODIUM; VALPROIC ACID; VIGABATRIN;

AGORAPHOBIA; ALCOHOL WITHDRAWAL; ANXIETY; ANXIETY DISORDER; BIPOLAR I DISORDER; CANNABIS ADDICTION; CLINICAL TRIAL; COCAINE DEPENDENCE; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; DRUG TOLERABILITY; HUMAN; IRRITABILITY; KLEPTOMANIA; NEUROTRANSMISSION; OBSESSIVE COMPULSIVE DISORDER; PANIC; POSTTRAUMATIC STRESS DISORDER; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SOCIAL PHOBIA; SOMATIZATION; SOMNOLENCE; SUBSTANCE ABUSE; WITHDRAWAL SYNDROME;

EID: 37049000593     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900015571     Document Type: Review

References (171)

1. Salzman C. New uses for lithium and anticonvulsants. Harv Rev Psychiatry. 2003;11:230-244.
2. Raby WN, Coomaraswamy S. Gabapentin reduces cocaine use among addicts from a community clinic sample. J Clin Psychiatry. 2004;65:84-86.
3. Andrews N, Loomis S, Blake R, Ferrigan L, Singh L, McKnight AT. Effect of gabapentin-like compounds on development and maintenance of morphine-induced conditioned place preference. Psychopharmacology (Berl). 2001;157:381-387.
4. Martinez-Raga J, Sabater A, Perez-Galvez B, Castellano M, Cervera G. Add-on gabapentin in the treatment of opiate withdrawal. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:599-601.
5. Campbell J, Nickel EJ, Penick EC, et al. Comparison of desipramine or carbamazepine to placebo for crack cocaine-dependent patients. Am J Addict. 2003;12:122-136.
6. Cornish JW, Maany I, Fudala PJ, et al. Carbamazepine treatment for cocaine dependence. Drug Alcohol Depend. 1995;38:221-227.
7. Kranzler HR, Bauer LO, Hersh D, Klinghoffer V. Carbamazepine treatment of cocaine dependences placebo-controlled trial. Drug Alcohol Depend. 1995;38:203-211.
8. Montoya ID, Levin FR, Fudala PJ, Gorelick DA. Double-blind comparison of carbamazepine and placebo for treatment of cocaine dependence. Drug Alcohol Depend. 1995;38:213-219.
9. Halikas JA, Crosby RD, Pearson VL, Graves NM. A randomized double-blind study of carbamazepine in the treatment of cocaine abuse. Clin Pharmacol Ther. 1997;62:89-105.
10. Schweizer E, Rickeis K, Case WG, Greenblatt DJ. Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy. Effects on withdrawal severity and outcome. Arch Gen Psychiatry. 1991;48:448-452.
11. Klein E, Uhde TW, Post RM. Preliminary evidence for the utility of carbamazepine in alprazolam withdrawal. Am J Psychiatry. 1986;143:235-236.
12. Ries RK, Roy-Byrne PP, Ward NG, Neppe V, Cullison S. Carbamazepine treatment for benzodiazepine withdrawal. Am J Psychiatry. 1989;146:536-537.
13. Cheseaux M, Monnat M, Zullino DF. Topiramate in benzodiazepine withdrawal. Hum Psychopharmacol. 2003;18:375-377.
14. Haney M, Hart CL, Vosburg SK, et al. Marijuana withdrawal in humans: effects of oral THC or Divalproex. Neuropsychopharmacology. 2004;29:158-170.
15. Levin FR, McDowell D, Evans SM, et al. Pharmacotherpy for marijuana dependence: a double-blind, placebo-controlled pilot study of divalproex sodium. Am J Addict. 2004;13:21-32.
16. Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: a randomized control trial. Lancet. 2003;361:1677-1685.
17. Johnson BA, Ait-Daoud N, Akhtar FZ, Ma JZ. Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals. Arch Gen Psychiatry. 2004;61:905-912.
18. Komanduri R. Two cases of alcohol craving curbed by topiramate. J Clin Psychiatry. 2003;65:612.
19. Rubio G, Ponce G, Jimenez-Arriero MA, Palomo T, Manzanares J, Ferre F. Effects of topiramate in the treatment of alcohol dependence. Pharmacopsychiatry. 2004;37:37-40.
20. Reoux JP, Saxon AJ, Malta CA, Baer JS, Sloan KL. Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial. Alcohol Clin Exp Res. 2001;25:1324-1329.
21. Bastie Y. Suppression des crises d'epilepsie du sevrage par le depakine dans les cures de desintoxication ethylique. Ann Med Psychol (Paris). 1970;2:400-404.
22. Brady KT, Myrick H, Henderson S, Coffey SF. The use of divalproex in alcohol relapse prevention: a pilot study. Drug Alcohol Depend. 2002;67:323-330.
23. Longo LP, Campbell T, Hubatch S. Divalproex sodium (Depakote) for alcohol withdrawal and relapse prevention. J Addict Dis. 2002;21:55-64.
24. Salloum IM, Cornelius JR, Daley DC, Kirisci L, Himmelhoch JM, Thase ME. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism. Arch Gen Psychiatry. 2005;62:37-45.
25. Malcolm R, Myrick H, Roberts J, Wand W, Anton RF, Ballenger JC. The effects of carbamazepine and lorazepam on single versus multiple previous alcohol withdrawals in an outpatient randomized trial. J Gen Intern Med. 2002;17:349-355.
26. Ritola E, Mahnen L. A double-blind comparison of carbamazepine and clomethiazole in the treatment of alcohol withdrawal syndrome. Acta Psychiatr Scand. 1981;64:254-259.
27. Flygenring J, Hansen J, Holst B, Peterson E, Sorensen A. Treatment of alcohol withdrawal symptoms in hospitalized patients. A randomized, double-blind comparison of carbamazepine (Tegretol) and barbital (Diemal). Acta Psychiatr Scand. 1984;69:398-408.
28. Stuppaeck CH, Pycha R, Miller C, Whitworth AB, Oberbauer H, Fleischhaker WW. Carbamazepine versus oxazepam in the treatment of alcohol withdrawal: a double-blind study. Alcohol Alcohol. 1992;27:153-158.
29. Stuppaeck CH, Barnas C, Hackenberg K, Miller CH, Fleishhacker WW. Carbamazepine monotherapy in the treatment of alcohol withdrawal. Int Clin Psychopharmacol. 1990;5:273-278.
30. Mueller TI, Stout RL, Rudden S, et al. A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence. Alcohol Clin Exp Res. 1997;21:86-92.
31. Bjorkqvist SE, Isohanni M, Makela R, Malinen L. Ambulant treatment of alcohol withdrawal symptoms with carbamazepine: a formal multicentre double-blind comparison with placebo. Acta Psychiatr Scand. 1976;53:333-342.
32. Myrick H, Malcolm R, Brady KT. Gabapentin treatment of alcohol withdrawal. Am J Psychiatry. 1998;155:1632.
33. Bonnet U, Banger M, Lewele FM, Maschke M, Kowalski T, Gastpar M. Treatment of alcohol withdrawal syndrome with gabapentin. Pharmacopsychiatry. 1999;32:107-109.
34. Bozikas V, Petrikis P, Gamvrula K, Sawidou I, Karavatos A. Treatment of alcohol withdrawal with gabapentin. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:197-1199.
35. Karam-Hage, Brower KJ. Gabapentin treatment for insomnia with alcohol dependence. Am J Psychiatry. 2000;157:2058-2059.
36. Bonnet U, Banger M, Leweke M, et al. Treatment of acute alcohol withdrawal with gabapentin: results from a controlled two-center trial. J Clin Psychopharmacol. 2003;23:514-519.
37. Voris J, Smith NL, Rao SM, Thorne DL, Flowers QJ. Gabapentin for the treatment of ethanol withdrawal. Subst Abus. 2003;24:129-132.
38. Stahl SM. Independent actions on fear circuits may lead to therapeutic synergy for anxiety when combining serotonergic and GABAergic agents. J Clin Psychiatry. 2002;63:854-855.
39. Coplan JD, Lydiard RB. Brain circuits in panic disorder. Biol Psychiatry. 1998;44:1264-1276.
40. Stutzmann GE, LeDoux JE. GABAergic antagonists block the inhibitory effects of serotonin in the lateral amygdala: a mechanism for modulation of sensory inputs related to fear conditioning. J Neurosci. 1999;19:RC8.
41. Taylor FB. Tiagabine for posttraumatic stress disorder: a case series of 7 women. J Clin Psychiatry. 2003;64:1421-1425.
42. Stahl SM. Essential Psychopharmacology of Depression and Bipolar Disorder. 2nd ed. New York, NY: Cambridge University Press; 2002.
43. Stahl SM. Anticonvulsants and the relief of chronic pain: pregabalin and gabapentin as alpha(2)delta ligands at voltage-gated calcium channels. J Clin Psychiatry. 2004;65:460-461.
44. Swann AC. Neuroreceptor mechanisms of aggression and its treatment. J Clin Psychiatry. 2003;64(suppl 4):26-35.
45. Van der Kolk BA. The psychobiology of PTSD. J Clin Psychiatry. 1997;58(suppl 9):16-24.
46. Clark RD, Canive JM, Calais LA, Qvalis CR, Tuason VB. Divalproex in posttraumatic stress disorder: an open label clinical trial. J Trauma Stress. 1999;12:395-401.
47. Frederick P, Davis L, Nugent A, et al. Valproate therapy for chronic, combat-induced posttraumatic stress disorder. J Clin Psychopharmacol. 2002;22:100-101.
48. Fesler FA. Valproate in combat-related posttraumatic stress disorder. J Clin Psychiatry. 1991;52:361-364.
49. Otte C, Wiedemann K, Yassouridis A, Kellner M. Valproate monotherapy in the treatment of civilian patients with non-combat-related posttraumatic stress disorder: an open-label study. J Clin Psychopharmacol. 2004;24:106-108.
50. Berigan TR, Holzgang A. Valproate as an alternative in posttraumatic stress disorder: a case report. Mil Med. 1995;160:318.
51. Brodsky L, Doerman AL, Palmer LS, Slade GF, Munasifi FA. Posttraumatic stress disorder: an eclectic approach. Int J Psychosom. 1990;37:89-95.
52. Szymanski HV, Olympia J. Divalproex in posttraumatic stress disorder. Am J Psychiatry. 1991;148:1086-1087.
53. Lipper S, Davidson JR, Grady TA, et al. Preliminary study of carbamazepine in post-traumatic stress disorder. Psychosomatics. 1986;27:849-854.
54. Viola J, Ditzler T, Batzer W, et al. Pharmacological management of post-traumatic stress disorder: clinical summary of a five-year retrospective study, 1990-1995. Mil Med. 1997;162:616-619.
55. Wolf ME, Alavi A, Mosnaim AD. Posttraumatic stress disorder in Vietnam veterans: clinical and EEG findings; possible therapeutic effects of carbamazepine. Biol Psychiatry. 1988;23:642-644.
56. Iancu I, Rosen Y, Moshe K. Antiepileptic drugs in posttraumatic stress disorder. Clin Neuropharmacol. 2002;25:225-229.
57. Stewart JT, Bartucci RJ. Posttraumatic stress disorder and partial complex seizures. Am J Psychiatry. 1986;143:113-114.
58. Hertzberg MA, Butterfield MI, Feldman ME, et al. A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry. 1999;45:1226-1229.
59. Bremner JD, Mletzko T, Welter S, et al. Treatment of posttraumatic stress disorder with phenytoin: an open-label pilot study. J Clin Psychiatry. 2004;65:1559-1564.
60. Berlant J, van Kammen DP. Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: a preliminary report. J Clin Psychiatry. 2002;63:15-20.
61. Van der Kolk BA. Psychopharmacology. Psychopharmacological issues in posttraumatic stress disorder. Hosp Community Psychiatry. 1983;34:683-691.
62. Kitchner I, Greenstein R. Low dose lithium carbonate in the treatment of post traumatic stress disorder: brief communication. Mil Med. 1985;150:378-381.
63. Forster PL, Schoenfeld FB, Marmar CR, Lang AJ. Lithium for irritability in post-traumatic stress disorder. J Trauma Stress. 1995;8:143-149.
64. Berigan TR. Gabapentin in the treatment of posttraumatic stress disorder. Prim Care Companion J Clin Psychiatry. 2002;2:105.
65. Brannon N, Labbate L, Huber M. Gabapentin treatment for posttraumatic stress disorder. Can J Psychiatry. 2000;45:84.
66. Malek-Ahmadi. Gabapentin and posttraumatic stress disorder. Ann Pharmacother. 2003;37:664-666.
67. Hamner MB, Broderick PS, Labbate LS. Gabapentin in PTSD: a retrospective, clinical series of adjunctive therapy. Ann Clin Psychiatry. 2001;13:141-146.
68. Schwartz TL. The use of tiagabine augmentation for treatment-resistant anxiety disorders: a case series. Psychopharmacol Bull. 2002;36:53-57.
69. MacLeod AD. Vigabatrin and posttraumatic stress disorder. J Clin Psychopharmacol. 1996;16:190-191.
70. Berigan T. Oxcarbazepine treatment of posttraumatic stress disorder. Can J Psychiatry. 2002;47:973-974.
71. Pande AC, Davidson JR, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol. 1999;19:341-348.
72. Blanco C, Schneier FR, Schmidt A, et al. Pharmacological treatment of social anxiety disorder: a meta-analysis. Depress Anxiety. 2003;18:29-40.
73. Simon NM, Worthington JJ, Doyle AC, et al. An open-label study of levetiracetam for the treatment of social anxiety disorder. J Clin Psychiatry. 2004;65:1219-1222.
74. Kinrys G, Pollack MH, Simon NM, Worthington JJ, Nardi AE, Versiani M. Valproic acid for the treatment of social anxiety disorder. Int Clin Psychopharmacol. 2003;18:169-172.
75. Jefferson JW. Benzodiazepines and anticonvulsants for social phobia (social anxiety disorder). J Clin Psychiatry. 2001;62(suppl 1):50-53.
76. Pande AC, Pollack MH, Crockett J, et al. Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol. 2000;20:467-471.
77. Layton ME, Friedman SD, Dager SR. Brain metabolic changes during lactate-induced panic: effects of gabapentin treatment. Depress Anxiety. 2001;14:251-254.
78. Baetz M, Bowen RC. Efficacy of divalproex sodium in patients with panic disorder and mood instability who have not responded to conventional therapy. Can J Psychiatry. 1998;43:73-77.
79. Primeau F, Fontaine R, Beauclair L. Valproic acid and panic disorder. Can J Psychiatry. 1990;35:248-250.
80. Woodman C, Noyes R. Panic disorder: treatment with valproate. J Clin Psychiatry. 1994;55:134-136.
81. Keck PE, Taylor VE, Tugrul KC, McElroy SL, Bennett JA. Valproate treatment of panic disorder and lactate-induced panic attacks. Biol Psychiatry. 1993;33:542-546.
82. Brady KT, Sonne S, Lydiard RB. Valproate treatment of comorbid panic disorder and affective disorders in two alcoholic patients. J Clin Psychopharmacol. 1994;14:81-82.
83. McElroy SL, Keck LPE, Lawrence JL. Treatment of panic disorder and benzodiazepine withdrawal with valproate. J Neuropsychiatry Clin Neurosci. 1991;2:232-233.
84. Roy-Byrne PP, Ward NG, Donnelly PJ. Valproate in anxiety and withdrawal sydromes. J Clin Psychiatry. 1989;50(suppl 3):44-48.
85. Ontiveros A, Fontaine R. Sodium valproate and clonazepam for treatment-resistent panic disorder. J Psychiatry Neurosci. 1992;17:78-80.
86. Marazziti D, Cassano GB. Valproic acid for panic disorder associated with multiple sclerosis. Am J Psychiatry. 1996;153:6-7.
87. Lum M, Fontaine R, Elie R, Ontiveros A. Divalproex sodium's antipanic effect in panic disorder: a placebo-controlled study. Biol Psychiatry. 1990;27:164A-165A.
88. Zwanger P, Baghai TC, Schule C, et al. Tiagabine improves panic and agoraphobia in panic disorder patients. J Clin Psychiatry. 2001;62:656-657.
89. Zwanger P, Eser D, Padberg F, et al. Effects of tiagabine on cholecystokinin tetrapeptide (cck-4) induced anxiety in health volunteers. Depress Anxiety. 2003;18:140-143.
90. Zwanger P, Baghai TC, Schule C, et al. Vigabatrin decreases cholecystokinin-tetrapeptide (cck-4) induced panic in healthy volunteers. Neuropsychopharmacol. 2001;25:699-703.
91. Tondo BL, Burrai C, Scamonatti L, et al. Carbamazepine in panic disorder. Am J Psychiatry. 1989;146:558-559.
92. Uhde TW, Stein MB, Post RM. Lack of efficacy of carbamazepine in the treatment of panic disorder. Am J Psychiatry. 1988;145:1104-1109.
93. Kaufman K, Gerner R. Adjunctive oxcarhazapine in comorbid anxiety and affective disorder with hyponatremic seizure: case analysis and literature review. Epilepsy Behav. 2003;4:766-770.
94. Windhaber J, Maierhofer D, Dantendorfer K. Oxcarbazepine for panic disorder occurring after two grand mal seizures: a case report. J Clin Psychiatry. 1997;58:404-405.
95. Rosenthal M. Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxitine as a positive control. J Clin Psychiatry. 2003;64:1245-1249.
96. Crane D. Tiagabine for the treatment of anxiety. Depress Anxiety. 2003;18:51-52.
97. Garcia-Campayo J, Sanz-Carrillo C. Gabapentin for the treatment of patients with somatization disorder. J Clin Psychiatry. 2001;62:474.
98. Garcia-Campayo J, Sanz-Carrillo C. Topiramate as a treatment for pain in multisomatoform disorder patients: an open trial. Gen Hosp Psychiatry. 2002;24:417-421.
99. McMeekin H. Successful treatment of obsessive compulsive disorder with oxcarbazepine. J S C Med Assoc. 2002;98:316-320.
100. Cora-Locatelli G, Greenberg BD, Martin, JD, Murphy DL. Valproate monotherapy in an SRI-intolerant OCD patient. J Clin Psychiatry. 1998;59:82.
101. Deltito JA. Valproate pretreatment for difficult-to-treat patient with OCD. J Clin Psychiatry. 1994;55:500.
102. Dannon PN. Topiramate for the treatment of kleptomania: a case series and review of the literature. Clin Neuropharmacol. 2003;26:1-4.
103. Burstein A. Fluoxetine-lithium treatment for kleptomania. J Clin Psychiatry. 1992;53:28-29.
104. Kmetz GF, McElroy SL, Collins DJ. Response of kleptomania and mixed mania to valproate. Am J Psychiatry. 1997;154:580-581.
105. McElroy SL, Pope HG, Hudson JI, Keck PE, White KL. Kleptomania: a report of 20 cases. Am J Psychiatry. 1991;148:652-657.
106. McElroy S, Arnold LM, Shapira N, et al. Topiramate in the treatment of binge-eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry. 2003;160:255-261.
107. McElroy SL, Shapira NA, Arnold LM, et al. Topiramate in the long-term treatment of binge-eating disorder associated with obesity. J Clin Psychiatry. 2004;65:1463-1469.
108. Appolinario JC, Fontenelle LF, Papelbaum M, Bueno JR, Coutinho W. Topiramate use in obese patients with binge eating disorder: an open study. Can J Psychiatry. 2002;47:271-273.
109. Shapira NA, Goldsmith TD, McElroy SL. Treatment of binge-eating disorder with topiramate: a clinical case series. J Clin Psychiatry. 2000;61:368-372.
110. Appolinario JC, Coutinho W, Fontenelle L. Topiramate for binge-eating disorder. Am J Psychiatry. 2001;158:967-968.
111. Prado-Lima SD, Bacaltchuck J. Topiramate in treatment-resistant depression and binge-eating disorder. Bipolar Disord. 2002;4:271-273.
112. McElroy SL, Kotwal R, Hudson JI, Nelson EB, Keck PE. Zonisamide in the treatment of being-eating disorder: an open-label, prospective trial. J Clin Psychiatry. 2004;65:50-56.
113. Hoopes SP, Reimherr FW, Hedges DW, et al. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 1: improvement in binge and purge measures. J Clin Psyhiatry. 2003;64:1335-1341.
114. Hedges DW, Reimherr FW, Hoopes SP, et al. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo controlled trial, part 2: improvement in psychiatric measures. J Clin Psychiatry. 2003;64:1449-1454.
115. Levy E, Margolese H, Chouniard G. Topiramate produced weight loss following olanzapine-induced weight gain in schizophrenia [letter]. J Clin Psychiatry. 2002;63:1045.
116. Van Ameringen M, Mancini C, Pipe B, Campbell M, Oakman J. Topiramate treatment for ssri-induced weight gain in anxiety disorders. J Clin Psychiatry. 2002;63:981-984.
117. Felstrom A, Blackshaw S. Topiramate for bulimia nervosa with bipolar II disorder [Letter]. Am J Psychiatry. 2002;159:1246-1247.
118. Colom F, Vieta E, Benabarre A, Martínez-Arán A, et al. Topiramate abuse in a bipolar patient with an eating disorder [letter]. J Clin Psychiatry. 2001;62:475-476.
119. Citrome L, Jaffe A, Levine J, Allingham B. Use of mood stabilizers among patients with schizophrenia, 1994-2001. Psychiatr Serv. 2002;53:1212.
120. Leucht S, McGrath J, Kissling W. Lithium for schizophrenia revisited: a systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry. 2004;65:177-186.
121. McEvoy JP, Scheifler PL, Frances A. The expert consensus guideline series: treatment of schizophrenia 1999. J Clin Psychiatry. 1999;60(suppl 11):43.
122. Citrome L. Schizophrenia and valproate. Psychopharmacol Bull. 2003;37(suppl 2):74-88.
123. Basan A, Kissling W, Leucht S. Valproate as an adjunct to antipsychotics for schizophrenia: a systematic review of randomized trials. Schizophr Res. 2004;70:33-37
124. Leucht S, McGrath J, White P, Kissling W. Carbamazepine augmentation for schizophrenia: how good is the evidence? J Clin Psychiatry. 2002;63:218-224.
125. Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association. Am J Psychiatry. 1997;154(4 suppl):1-63.
126. Miller AL, Chiles JA, Chiles JK, Crismon ML, Rush AJ, Shon SP. The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms. J Clin Psychiatry. 1999;60:649-657.
127. Leucht S, McGrath J, White P, Kissling W. Carbamazepine for schizophrenia and schizoaffective psychosis. Cochrane Database Syst Rev. 2002;(3):CD001258.
128. Dose M, Apelt S, Emrich HM. Carbamazepine as an adjunct of antipsychotic therapy. Psychiatry Res. 1987;22:303-310.
129. Hesslinger B, Normann C, Langosch JM, et al. Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients. J Clin Psychopharmacol. 1998;19:310-315.
130. Martin-Munoz JC, Morinigo-Dominguez AV, Mateo-Martin I, et al. La carbamacepina: un tratamiento adjunto eficaz en las esguizofrenias. Actas Luso Esp Neurol Psiquiatr Cienc Afines. 1989;17:245-250
131. Nachshoni T, Levin Y, Levy A, et al. A double-blind trial of carbamazepine in negative symptom schizophrenia. Biol Psychiatry. 1994;35:22-26
132. Neppe VM. Carbamazepine as adjunctive treatment in nonepileptic chronic inpatients with EEG temporal lobe abnormalities. J Clin Psychiatry. 1983;44:326-331.
133. Simhandl C, Meszaros K, Denk E, et al. Adjunctive carbamazepine or lithium carbonate in therapy-resistant chronic schizophrenia. Can J Psychiatry. 1996;41:317.
134. Okuma T, Yamashita I, Takahashi R, et al. A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders. Acta Psychiatr Scand. 1989;80:250-259.
135. Klein E, Bental E, Lerer B, Belmaker RH. Carbamazepine and haloperidol v placebo and haloperidol in excited psychoses. A controlled study. Arch Gen Psychiatry. 1984;41:165-170.
136. Tiihonen J, Hallikainen T, Ryynänen OP, et al. Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biol Psychiatry. 2003;54:1241-1248.
137. Kremer I, Vass A, Gorelik I, et al. Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. Biol Psychiatry. 2004;56:441-446.
138. Hillbom M, Tokola R, Kuusela V, et al. Prevention of alcohol withdrawal seizures with carbamazepine and valproic acid. Alcohol. 1989;6:223-236.
139. Salinsky MC, Binder LM, Oken BS, Storzbach D, Aran CR, Dodrill CB. Effects of gabapentin and carbamazepine on the EEG and cognition in healthy volunteers. Epilepsia. 2002;43:482-490.
140. Meador KJ, Loring DW, Ray PG, et al. Differential cognitive and behavioral effects of carbamazepine and lamotrigine. Neurology. 2001;56:1177-1182.
141. Rawson NS, Harding SR, Malcolm E, Lueck L. Hospitalizations for aplastic anemia and agranulocytosis in Saskatchewan: incidence and associations with antecedent prescription drug use. J Clin Epidemiol. 1998;51:1343-1355.
142. Ibáñez L, Vidal X, Ballarín E, Laporte JR. Population-based drug-induced agranulocytosis. Arch Intern Med. 2005;165:869-874.
143. Ono S, Mihara K, Suzuki A, et al. Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes. Psychopharmacology (Berl). 2002;162:50-54.
144. Lucas RA, Gilfillan DJ, Bergstrom RF. A pharmacokinetic interaction between carbamazepine and olanzapine: observations and possible mechanism. Eur J Clin Pharmacol. 1998;54:639-643.
145. Sussman NM, McLain LW Jr. A direct hepatotoxic effect of valproic acid. JAMA. 1979;242:1173-1174.
146. Biton V, Mirza W, Montouris G, Vuong A, Hammer AE, Barrett PS. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology. 2001;56:172-177.
147. Corman CL, Leung NM, Guberman AH. Weight gain in epileptic patients during treatment with valproic acid: a retrospective study. Can J Neurol Sci. 1997;24:240-244.
148. Wen X, Wang JS, Kivistö KT, Neuvonen PJ, Backman JT. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). Br J Clin Pharmacol. 2001;52:547-553.
149. Parsons B, Tive L, Huang S. Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. Am J Geriatr Pharmacother. 2004;2:157-162.
150. Galindo PA, Borja J, Gómez E, et al. Anticonvulsant drug hypersensitivity. J Investig Allergol Clin Immunol. 2002;12:299-304.
151. Wong IC, Mawer GE, Sander JW. Factors influencing the incidence of lamotrigine-related skin rash. Ann Pharmacother. 1999;33:1037-1042.
152. Mackay FJ, Wilton LV, Pearce GL, Freemantle SN, Mann RD. Safety of long-term lamotrigine in epilepsy. Epilepsia. 1997;38:881-886.
153. Huang CW, Tsai JJ, Lai ML. Lamotrigine-related skin rashes in adults. Kaohsiung J Med Sci. 2002;18:566-572.
154. Abou-Khalil B. Benefit-risk assessment of levetiracetam in the treatment of partial seizures. Drug Saf. 2005;28:871-890.
155. Ben-Menachem E, Gilland E. Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy. Seizure. 2003;12:131-135.
156. Cereghino JJ, Biton V, Abou-Khalil B, Dreifuss F, Gauer LJ, Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology. 2000;55:236-242.
157. Betts T, Waegmans T, Crawford P. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. Seizure. 2000;9:80-87.
158. Deodhar SD, Singh B, Pathak CM, Sharan P, Kulhara P. Thyroid functions in lithium-treated psychiatric patients: a cross-sectional study. Biol Trace Elem Res. 1999;67:151-163.
159. Marini JL, Sheard MH. Sustained-release lithium carbonate in double-blind study: serum lithium levels, side effects, and placebo response. J Clin Pharmacol. 1976;16:276-283.
160. Gelenberg AJ, Kane JM, Keller MB, et al. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Engl J Med. 1989;321:1489-1493.
161. Bendz H, Sjödin I, Aurell M. Renal function on and off lithium in patients treated with lithium for 15 years or more. A controlled, prospective lithium-withdrawal study. Nephrol Dial Transplant. 1996;11:457-460.
162. Pendlebury SC, Moses DK, Eadie MJ. Hyponatremia during oxcarbazepine therapy. Hum Toxicol. 1989;8:337-344.
163. Scheinfeld N. Impact of Phenytoin therapy on the skin and skin disease. Expert Opin Drug Saf. 2004;3:655-665.
164. Suppes T, Chisholm KA, Dhavale D, et al. Tiagabine in treatment refractory bipolar disorder: a clinical case series. Bipolar Disord. 2002;4:283-289.
165. Kalviainen R, Brodie MJ, Duncan J, Chadwick D, Edwards D, Lyby K. A double-blind, placebo-controlled trial of tiagabine given three-times daily as add-on therapy for refractory partial seizures. Epilepsy Res. 1998;30:31-40.
166. Uthman BM, Rowan AJ, Ahmann PA, et al. Tiagabine for complex partial seizures: a randomized, add-on, dose-response trial. Arch Neurol. 1998;55:56-62.
167. Fritz N, Glogau S, Hoffmann J, Rademacher M, Elger CE, Helmstaedter C. Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy. Epilepsy Behav. 2005;6:373-381.
168. Thompson PJ, Baxendale SA, Duncan JS, Sander JW. Effects of topiramate on cognitive function. J Neurol Neurosurg Psychiatry. 2000;69:636-641.
169. Malmgren K, Ben-Menachem E, Frisén L. Vigabatrin visual toxicity: evolution and dose dependence. Epilepsia. 2001;42:609-165.
170. Mesa F, Aguilar M, Gonzalez-Moles MA, et al. Vigabatrin-induced modification of Ki-67 expression in gingival epithelium: immunohistochemical study of a short series. J Periodontal Res. 2004;39:66-71.
171. Lippik IE, Willmore LJ, Homan RW, et al. Efficacy and safety of zonisamide: results of a multicenter study. Epilepsy Res. 1993;14:165-173.